Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Bicalutamide and spironolactone are being compared for their effectiveness and safety in treating female pattern hair loss. The conversation seeks advice on which is better to use.

The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.

The user has been taking oral Finasteride and topical Essengen 6 Plus for hair loss and is experiencing increased depression. They plan to get bloodwork to check hormone levels and are seeking advice on which tests to include.

Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.

The conversation discusses various hair loss treatments, including Breezula, KX826, and PP405, with mixed opinions on their effectiveness compared to finasteride and minoxidil. Some users express skepticism about the new treatments, while others remain hopeful about future developments.

The conversation discusses the potential benefits and risks of participating in the PP405 hair loss trials, emphasizing that those using Minoxidil or finasteride are less likely to be accepted. Participants are interested in the trial as it offers hope for effective treatment without the side effects associated with current medications.

The user is considering blood tests to understand their receding hairline and is exploring brewer's yeast for its biotin content. They have been using topical Minoxidil, biotin, collagen, and microneedling, but are avoiding oral Finasteride and Dutasteride.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

A 25-year-old male is concerned about his blood test results, particularly the low percentage of free testosterone, and is questioning whether starting finasteride for hair loss might worsen this issue. He also notes a slight vitamin D deficiency and lack of sleep before the test.

A user ordered Alpha Plus from Anagenica, expecting it to contain specific percentages of Fin, Estradiol, Minoxidil, and CB0301. However, the received product's label showed different percentages, including a surprising 25% CB, leading the user to question its safety and accuracy.

User experienced good results with topical finasteride, noting reduced DHT and increased testosterone. They plan to revert to a lower dosage after observing slight libido reduction.

The conversation is about comparing hair loss treatments Pyrilutamide (KX-826) and CB-03-01, discussing their cost, side effects, and effectiveness. The user questions whether to try CB-03-01, which is more expensive and potentially less effective, or switch to the cheaper and possibly better Pyrilutamide.

Researching the release of phase 2 trials for pyrilutamide, a potential hair loss treatment, and discussing other treatments such as Minoxidil, Finasteride, and RU58841.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

Hairgenetix Copper Peptide Serum and PeptideLabz GHK-Cu + AHK-Cu Serum are being compared for effectiveness in hair loss treatment. The user is seeking recommendations for other brands with authentic reviews.

The user experienced genital itching while using finasteride and noticed a yellow bump, which improved with clotrimazole, but the itching persists. The discussion focuses on side effects of finasteride.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

The user is taking finasteride for hair loss and is considering adding Resveratrol and Bio-Quercetin supplements for general wellbeing. They are concerned about potential interactions affecting the effectiveness of finasteride.

Scube3 trials have not started yet. Treatments discussed include Minoxidil, finasteride, and RU58841.

Users discussed experiences with Everychem's solution similar to PP405 for hair loss, noting some positive results like increased hair thickness and new growth. There was skepticism about the product's legitimacy and safety, with some users reporting early signs of effectiveness and others expressing concerns about the lack of evidence and safety profiles.

The user has been treating hair loss for over 11 years with various methods including Minoxidil, Keto shampoos, vitamins, and microneedling, but has avoided Finasteride due to fertility concerns. They have recently added Zix and The Ordinary Serum to their routine and are questioning their high DHT levels despite their efforts.

GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

The conversation discusses the use of KX826 for hair loss, with mixed opinions on its effectiveness. Some users are skeptical, mentioning no significant progress or regrowth, and others suggest it might be a scam or that data may be manipulated.

The conversation humorously discusses a visit to the Everychem laboratory, with a focus on hair loss treatments like Minoxidil, finasteride, and RU58841. The tone is satirical.

The conversation is about the progress of clinical trials for SCUBE3, a potential hair loss treatment. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

User received Trichotest results not recommending Finasteride. They are on Oral Minoxidil 2.50 and considering adding Finasteride.

The user is considering resuming finasteride after a 6-month break and is debating the necessity of extensive blood work, including hormone and health markers, to establish a baseline. They are unsure if the tests are necessary since they experienced no side effects previously.

The user is taking 1mg Dutasteride, 2.5mg oral Minoxidil, topical Minoxidil, 28mg iron, vitamin D3 + K2, and Selenium daily. They are concerned about their receding hairline despite good hair density and crown.

TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.